Bilha Schechter

Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy

Lilach M. Friedman, Ariel Rinon, Bilha Schechter et al. · Proceedings of the National Academy of Sciences · 2005 · 258 citations · Full text

Cancer Research, Cancer Immunosurveillance, Signal Transduction +15

Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis

Tsipi Ben-Kasus, Bilha Schechter, Sara Lavi et al. · Proceedings of the National Academy of Sciences · 2009 · 166 citations · Full text

Distinct Epitope, Receptor Endocytosis, Immunology +18

Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth

Georg Mahlknecht, Ruth Maron, Maicol Mancini et al. · Proceedings of the National Academy of Sciences · 2013 · 158 citations · Full text

Antibodies to Sequential and Conformational Determinants

Michael Sela, Bilha Schechter, Israël Schechter et al. · Cold Spring Harbor Symposia on Quantitative Biology · 1967 · 157 citations

Conformational Determinants, Protein Assembly, Molecular Biology +21

MRI and fluorescence microscopy of the acute vascular response to VEGF165: vasodilation, hyper‐permeability and lymphatic uptake, followed by rapid inactivation of the growth factor

Hagit Dafni, Limor Landsman, Bilha Schechter et al. · NMR in Biomedicine · 2002 · 101 citations · Full text